<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579525</url>
  </required_header>
  <id_info>
    <org_study_id>TARTARE-2S-01</org_study_id>
    <nct_id>NCT02579525</nct_id>
  </id_info>
  <brief_title>Targeted Tissue Perfusion Versus Macrocirculatory-guided Standard Care in Patients With Septic Shock</brief_title>
  <acronym>TARTARE-2S</acronym>
  <official_title>Targeted Tissue Perfusion Versus Macrocirculatory-guided Standard Care in Patients With Septic Shock [TARTARE-2S]- A Multicentre Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The recommended monitoring and target levels in septic shock (SSC Guidelines&#xD;
      2012) including mean arterial pressure (MAP) target are not based on robust clinical data.&#xD;
&#xD;
      Objective: To test, if in patients with septic shock, tissue perfusion guided (TPG) treatment&#xD;
      strategy leads to a faster resolution of hypoperfusion than the macrocirculatory target&#xD;
      guided standard care.&#xD;
&#xD;
      Design: A prospective phase II two-parallel-group open-label randomized controlled trial&#xD;
&#xD;
      Interventions:&#xD;
&#xD;
        1. Intervention group- Targeted tissue perfusion guided (TTP) - care.&#xD;
&#xD;
        2. Control group - Macrocirculatory - guided (MCG) care.&#xD;
&#xD;
      Randomization: 1:1 stratified according to the site and presence or absence of known&#xD;
      hypertension.&#xD;
&#xD;
      Trial size: 200 randomised patients in 4 ICUs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study hypothesis: Targeting at clinical tissue perfusion (in the TTP arm) will decrease the&#xD;
      use and untoward effects of vasopressors, and result in more days alive in 30-days without&#xD;
      vasopressor or inotropic support and without lactatemia, in comparison with standard clinical&#xD;
      care with preference of macrocirculatory targets (MCG arm).&#xD;
&#xD;
      Intervention group - Targeted tissue perfusion (TTP) care:&#xD;
&#xD;
      Primary targets /registration period&#xD;
&#xD;
        1. capillary refill time (CRT) / &lt;3 sec/ every hour&#xD;
&#xD;
        2. skin mottling / absent / every hour&#xD;
&#xD;
        3. arterial lactate / &lt;2.0 mmol/l/ per 2hr&#xD;
&#xD;
        4. peripheral temperature/ warm /every hour&#xD;
&#xD;
        5. urine output/ ≥0.5 mL/kg per hour/ every hour&#xD;
&#xD;
        6. mean arterial pressure (MAP) 50-65 mmHg (minimum as a safety limit)/ continuous&#xD;
&#xD;
             -  if previous hypertension 65- 70 mmHg&#xD;
&#xD;
             -  if oliguria 2-hour trial 75-80 mmHg (If diuresis better, continue 2hr and&#xD;
                re-evaluate) Secondary target&#xD;
&#xD;
        7. Continuous mixed venous saturation (SvO2) &gt;65%, if available&#xD;
&#xD;
      Control group - Macrocirculatory targets guided (MCG) standard care Primary targets&#xD;
&#xD;
        1. Mean arterial pressure (MAP) 65-75 mmHg /continuous&#xD;
&#xD;
           ** if previous hypertension 75-80 mmHg&#xD;
&#xD;
           *** if oliguria &lt; 0.3 ml/kg, 2-hour trial 85-90 mmHg (If diuresis better, continue 2hr&#xD;
           and re-evaluate)&#xD;
&#xD;
        2. Central venous pressure (CVP)/hourly, Adequate fluid therapy is indicated to restore&#xD;
           clinical hypovolemia up to the recommended CVP-level of 8-12 mmHg, if needed&#xD;
&#xD;
        3. Urine output ≥ 0.5 mL/kg/h/ hourly Secondary target&#xD;
&#xD;
        4. Continuous SvO2 &gt;65%, if available&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days alive in 30 days- without vasopressors/ inotropes or hyperlactatemia</measure>
    <time_frame>30 days</time_frame>
    <description>• Days alive in 30 days with normal arterial blood lactate ( first confirmed value of &lt; 2 mmol/L) AND without any inotropic or vasopressor agent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to normalization of arterial blood lactate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive with normal arterial blood lactate in 30 days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive without any inotropic or vasopressor agent in 30 days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive without renal replacement therapy (RRT) in 30 days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive without mechanical ventilation in 30 days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive without any organ support (mechanical ventilation, renal-replacement therapy, vasopressor/ inotropic agents) in 30 days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New acute kidney injury (AKI) (Kdigo stages I-III)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive outside hospital in 90 days</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of norepinephrine given up to day 5</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number/ total number of the following adverse reactions</measure>
    <time_frame>30 days</time_frame>
    <description>ventricular tachycardia/ fibrillation , atrial fibrillation , myocardial infarction , skin necrosis , stroke , secondary bowel ischemia, limb ischemia, numbers of serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Shock; Septic</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Targeted tissue perfusion guidance (TTP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTP-guidance based on clinical signs of peripheral perfusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Macrocirculatory - guidance (MCG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MCG-guidance based on recommended macrocirculatory parameters.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hemodynamical treatment TTP</intervention_name>
    <description>Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring</description>
    <arm_group_label>Targeted tissue perfusion guidance (TTP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hemodynamical treatment MCG</intervention_name>
    <description>Based on MAP, CVP, urine output monitoring</description>
    <arm_group_label>Macrocirculatory - guidance (MCG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Septic shock defined as&#xD;
&#xD;
               1. Septic infection AND&#xD;
&#xD;
               2. systemic mean blood pressure &gt; 65 mmHg requiring any dose of vasopressors&#xD;
                  (norepinephrine, vasopressin) despite adequate fluid resuscitation (minimum of 20&#xD;
                  ml/kg crystalloids) AND&#xD;
&#xD;
               3. Elevated lactate ≥ 3.0 mmol/L with suspected hypoperfusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  aged less than 18 or over 80 years&#xD;
&#xD;
          -  any other probable condition than sepsis affecting or expected to affect the central&#xD;
             nervous system including post cardiac arrest&#xD;
&#xD;
          -  present or suspected myocardial ischemia&#xD;
&#xD;
          -  acute pulmonary embolism&#xD;
&#xD;
          -  terminal illness and not considered for full intensive care support&#xD;
&#xD;
          -  use of extra-corporeal membrane oxygenation (ECMO)&#xD;
&#xD;
          -  known liver disease - Child-Pugh -Class B or C&#xD;
&#xD;
          -  confirmed chronic kidney disease known on admission&#xD;
&#xD;
          -  known to be pregnant or lactating&#xD;
&#xD;
          -  more than 4 hours from fulfilled inclusion criteria to randomization&#xD;
&#xD;
          -  another probable cause of hyperlactatemia&#xD;
&#xD;
          -  patients transferred from another ICU&#xD;
&#xD;
          -  patients with active haematological malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ville Pettilä, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Hospital/ Bern University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Jakob, Prof, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ville Pettilä, Prof</last_name>
    <phone>0504271715</phone>
    <phone_ext>+358</phone_ext>
    <email>ville.pettila@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Jakob, Prof, Dr Med</last_name>
    <email>stephan.jakob@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ville Pettilä, Prof</last_name>
      <phone>+35894271715</phone>
      <email>ville.pettila@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Ville Pettilä, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erika Wilkman, A/P</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Jakob, Prof</last_name>
      <email>stephan.jakob@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Stephan Jakob, Prof, Dr Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Varis E, Pettilä V, Poukkanen M, Jakob SM, Karlsson S, Perner A, Takala J, Wilkman E; FINNAKI Study Group. Evolution of Blood Lactate and 90-Day Mortality in Septic Shock. A Post Hoc Analysis of the FINNAKI Study. Shock. 2017 May;47(5):574-581. doi: 10.1097/SHK.0000000000000772.</citation>
    <PMID>27755509</PMID>
  </reference>
  <reference>
    <citation>Pettilä V, Merz T, Wilkman E, Perner A, Karlsson S, Lange T, Hästbacka J, Hjortrup PB, Kuitunen A, Jakob SM, Takala J. Targeted tissue perfusion versus macrocirculation-guided standard care in patients with septic shock (TARTARE-2S): study protocol and statistical analysis plan for a randomized controlled trial. Trials. 2016 Aug 2;17:384. doi: 10.1186/s13063-016-1515-x.</citation>
    <PMID>27484695</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Ville Pettilä</investigator_full_name>
    <investigator_title>Professor of Intensive Care Medicine</investigator_title>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>tissue perfusion</keyword>
  <keyword>macrocirculatory</keyword>
  <keyword>mean arterial pressure</keyword>
  <keyword>vasopressor use</keyword>
  <keyword>days alive free of organ support</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

